Vasopressin: a new target for the treatment of heart failure.

[1]  K. Kikuchi,et al.  Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor , 1999, Molecular and Cellular Biochemistry.

[2]  J. Ouyang,et al.  Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination , 2002 .

[3]  M. Gheorghiade,et al.  Vasopressin receptor blockade with tolvaptan in chronic heart failure: differential effects in normonatremic and hyponatremic patients , 2002 .

[4]  J. Ghali,et al.  Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure , 2001 .

[5]  J. Frøkiaer,et al.  Physiology and pathophysiology of renal aquaporins. , 1999, Journal of the American Society of Nephrology : JASN.

[6]  D. Nisato,et al.  Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure. , 2000, The Journal of pharmacology and experimental therapeutics.

[7]  K. Kikuchi,et al.  Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. , 2000, European journal of pharmacology.

[8]  Y. Yamamura,et al.  Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. , 2000, The Journal of pharmacology and experimental therapeutics.

[9]  M. Burnier,et al.  Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects , 1999, European Journal of Clinical Pharmacology.

[10]  W. Abraham,et al.  Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. , 1999, Journal of the American Society of Nephrology : JASN.

[11]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[12]  K. Honda,et al.  Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. , 1999, European journal of pharmacology.

[13]  L. Burrell,et al.  Vasopressin V2 receptor enhances gain of baroreflex in conscious spontaneously hypertensive rats. , 1999, The American journal of physiology.

[14]  Marvin A. Konstam,et al.  Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. , 1999, Journal of cardiac failure.

[15]  T. Iijima,et al.  On the inotropic actions of arginine vasopressin in ventricular muscle of the guinea pig heart. , 1999, Japanese journal of pharmacology.

[16]  T Yamashita,et al.  OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. , 1998, The Journal of pharmacology and experimental therapeutics.

[17]  C. Johnston,et al.  Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. , 1998, American journal of physiology. Heart and circulatory physiology.

[18]  J. Tsukada,et al.  Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. , 1998, Cardiovascular research.

[19]  J. Taylor,et al.  VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. , 1998, Advances in experimental medicine and biology.

[20]  R. Schrier,et al.  Recent advances in the understanding of water metabolism in heart failure. , 1998, Advances in experimental medicine and biology.

[21]  M. Takanashi,et al.  Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. , 1997, The Journal of pharmacology and experimental therapeutics.

[22]  R. Schrier,et al.  Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. , 1997, The Journal of clinical investigation.

[23]  T. Takenaka,et al.  Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs. , 1997, European journal of pharmacology.

[24]  C. S. Gal,et al.  Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. , 1996, The Journal of clinical investigation.

[25]  L. Goldman,et al.  Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. , 1996, Archives of internal medicine.

[26]  Y. Yamamura,et al.  Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. , 1995, The Journal of pharmacology and experimental therapeutics.

[27]  T. Saruta,et al.  Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. , 1994, The American journal of physiology.

[28]  T. Sugimoto,et al.  Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. , 1994, The Journal of biological chemistry.

[29]  M. Thibonnier,et al.  Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. , 1994, The Journal of biological chemistry.

[30]  P. Meda,et al.  [Ca2+]i and protein kinase C in vasopressin-induced prostacyclin and ANP release in rat cardiomyocytes. , 1994, The American journal of physiology.

[31]  K. Yoshinaga,et al.  Central effects of endothelin-1 on vasopressin release, blood pressure, and renal solute excretion. , 1992, The American journal of physiology.

[32]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[33]  B. Walker,et al.  Direct cardiac effects of vasopressin: role of V1- and V2-vasopressinergic receptors. , 1988, The American journal of physiology.

[34]  S. Goldsmith,et al.  Vasopressin as vasopressor. , 1987, The American journal of medicine.

[35]  J. Cohn,et al.  Hemodynamic effects of infused arginine vasopressin in congestive heart failure. , 1986, Journal of the American College of Cardiology.

[36]  G. Francis,et al.  Arginine vasopressin and the renal response to water loading in congestive heart failure. , 1986, The American journal of cardiology.

[37]  T. Ryan,et al.  Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. , 1986, Journal of the American College of Cardiology.

[38]  A. Cowley,et al.  Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man. , 1986, The Journal of clinical investigation.

[39]  K. Yoshinaga,et al.  Role of intracerebral angiotensin receptors in the regulation of vasopressin release and the cardiovascular system. , 1986, Neuroendocrinology.

[40]  J. Goy,et al.  Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. , 1985, The American journal of cardiology.

[41]  E. Kirk,et al.  Effects of vasopressin on the coronary circulation: reserve and regulation during ischemia. , 1985, The American journal of physiology.

[42]  J. Cohn,et al.  Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.

[43]  M. Faure,et al.  Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture. , 1983, The American journal of physiology.

[44]  T. Berl,et al.  Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. , 1981, The New England journal of medicine.

[45]  A. Guyton,et al.  Textbook of Medical Physiology , 1961 .